| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Hims & Hers Health, Inc.$24.85
-4.59 (-15.64%)
Market Cap
4.43 B
EPS
0.57
P/E Ratio
37.22 $
Value Trade
371.06 M
SEC Financials
Q1 2026Dilution Risk
Revenue
608.10 M
Operating CF
89.36 M
Total Assets
2.27 B
Total Liabilities
1.82 B
Equity
446.17 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
750.88 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
25.37 M
52 Week Range
13.74 - 70.43
% held by Insiders
9.78 %
% held by Institutions
66.29 %
Enterprise Value
4.97 B
Total Shares
222.67 M
Short %
29.41 %
Float Shares
194.61 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HIMS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HIMS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-HIMS
Jul 29, 2026▼ -15.6%today
Hims & Hers Responds to FTC Lawsuit
Hims & Hers Health, Inc. has responded to a lawsuit filed by the FTC, claiming the lawsuit disregards evidence provided during a lengthy investigation. The company argues that the FTC's actions misinterpret telehealth laws and are aimed at generating negative publicity rather than protecting consumers. Hims & Hers asserts that the lawsuit is unfounded and misleading.
Read more →-HIMS
Jul 17, 2026Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
Hims & Hers Health, Inc. announced the departure of Chief Accounting Officer Irene Becklund, effective October 9, 2026, after over seven years with the company. Becklund will aid in the transition as an advisor for several months. The company is beginning a search for her permanent successor, with CFO Yemi Okupe taking on her responsibilities temporarily.
Read more →-HIMS
Jul 13, 2026Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
Hims & Hers Health, Inc. will announce its second quarter 2026 financial results on August 10, 2026, after market close. A live conference call is scheduled for the same day at 5:00 p.m. ET to discuss these results. Participants can join via specific dialing instructions provided.
Read more →-HIMS
Jun 2, 2026Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform
Hims & Hers has successfully completed the acquisition of Eucalyptus, reinforcing its status as the largest consumer health platform globally. This strategic move is expected to enhance their service offerings and market presence. The acquisition reflects Hims & Hers' commitment to expanding its portfolio in the consumer health sector.
Read more →-HIMS
Jun 2, 2026Document Hims Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform The acquisition extends the company's leadership position across Australia, Canada, Germany,
Hims Hers Health, Inc. has completed its acquisition of Eucalyptus, further solidifying its position as the world's largest consumer health platform. This strategic move expands Hims Hers' reach across multiple countries, including Australia, Canada, Germany, Japan, and the UK. The company aims to leverage Eucalyptus' regional presence and customer-first approach to enhance its services globally. Hims Hers has ambitious financial targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030 as it continues to innovate in digital health delivery.
Read more →-HIMS
May 28, 2026Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
Hims & Hers has announced the expansion of benefits for its active subscribers by partnering with eight new health and wellness providers. This initiative is designed to enhance the overall health offerings available to subscribers, aiming to improve their satisfaction and engagement with the platform.
Read more →-HIMS
May 21, 2026Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
Hims & Hers has expanded its GLP-1 offering in Canada by introducing a generic version of semaglutide. This move aims to enhance accessibility for patients seeking treatment options. The expansion reflects the company's commitment to providing affordable healthcare solutions.
Read more →-HIMS
May 21, 2026Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
Hims & Hers has announced the introduction of generic Semaglutide to the Canadian market, marking a significant step in expanding access to this medication. This initiative aims to provide more affordable treatment options for patients managing conditions such as obesity and diabetes. The availability of generics is expected to benefit consumers by reducing costs.
Read more →-HIMS
May 21, 2026Hims & Hers offre un accès inédit au sémaglutide générique au Canada
Hims & Hers has announced the availability of generic semaglutide in Canada. This move is expected to enhance access to this medication for Canadian patients. Further details regarding the implications of this launch were not provided in the article.
Read more →-HIMS
May 19, 2026Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Health, Inc. has announced an upsized offering of $350 million in convertible senior notes. The funds will be used to support the company's international expansion and enhance its AI-driven platform. This move reflects the company's commitment to growth and innovation in the healthcare sector.
Read more →-HIMS
May 18, 2026▼ -11%on this newsshared move
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment Proceeds intended to be used to preserve financial flexibility
Hims & Hers Health, Inc. announced a proposed offering of $300 million in convertible senior notes due 2032 to support its international expansion and accelerate investment in AI-based platforms. The proceeds are intended to enhance operational infrastructure and technology while preserving financial flexibility. The company also plans to use some of the funds for a proposed acquisition of Eucalyptus, anticipated to close in mid-2026, subject to regulatory approvals. However, uncertainties remain regarding the offering's final terms and potential market conditions.
Read more →-HIMS
May 18, 2026▼ -11%on this newsshared move
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Health, Inc. has announced a proposed offering of convertible senior notes. The funds are intended to support the company's international expansion and enhance investments in its AI-driven platform. This move reflects the company's strategic focus on growth and technology integration.
Read more →-HIMS
May 11, 2026Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
Hims & Hers Health, Inc. has released its financial results for the first quarter of 2026. The report highlights the company's performance metrics, although specific details were not provided in the article. The focus remains on the company's ongoing strategies and market positioning.
Read more →-HIMS
Apr 28, 2026▼ -5%on this news
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors
Hims & Hers Health, Inc. has nominated Kofi Amoo-Gottfried for election to its board of directors at the 2026 annual shareholder meeting. Amoo-Gottfried, a seasoned marketing leader, has significant experience with transformative brands. His nomination is part of the company's strategy to enhance its leadership and continue its mission of improving health experiences for consumers.
Read more →-HIMS
Apr 13, 2026▲ +8.9%on this news· ran to +39% by day 3
Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026
Hims & Hers is set to announce its financial results for the first quarter of 2026 on May 11, 2026. This announcement is part of the company's regular reporting schedule. Further details regarding the financial performance will be disclosed at that time.
Read more →-HIMS
Mar 9, 2026▲ +40.8%on this news· ran to +51% by day 3
Document Hims Hers announces strategic shift for US weight loss business Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasin
Hims Hers Health, Inc. announced a strategic shift for its US weight loss business through a collaboration with Novo Nordisk, focusing on FDA-approved GLP-1 medications. This new strategy entails discontinuing compounded GLP-1 offerings and providing customers access to approved treatments like Ozempic and Wegovy. The company's goal is to become a leading global consumer health platform with diverse medication options. Further, Hims Hers will educate users about these new offerings and support clinical transitions for patients as necessary.
Read more →-HIMS
May 8, 2025Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare Proceeds intended to support Hims & Hers global expansion through organic g
Hims & Hers Health, Inc. has announced a proposed offering of $450 million in convertible senior notes to finance its global expansion and enhance its healthcare technology through AI. The offering includes an option for additional notes, and the funds will also bolster the company's newly appointed CTO's initiative to develop AI tools and personalize treatments. While no material acquisitions are currently planned, the funds are aimed at supporting organic growth. The notes are set to mature in 2030 and feature convertible and redeemable options for noteholders, contributing to potential dilution of shares depending on conversion outcomes.
Read more →-HIMS
Feb 4, 2022C ONSOLIDATED F INANCIAL S TATEMENTS Hims, Inc. and Subsidiaries Years Ended
Hims, Inc. and Subsidiaries Years Ended December 31, 2020 and 2019 With Report of Independent Registered Public Accounting Firm Hims, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Report of Independent Registered Public Accou
Read more →Competitive Position
How HIMS ranks across every disease it competes inCompetitive Position is a premium feature
See how HIMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial